Novozymes tastes robust sales in Q3 2014

Novozymes announced 9 percent growth within Q3. According to the company, its robust sales in spite of an uncertain economic climate were driven by relevant innovations targeting a variety of markets and industries


Mr Peder Holk Nielsen, CEO, Novozymes

"Like nature, our business is truly diverse," said Mr Peder Holk Nielsen, Novozymes' CEO. "Through combining industrial insight with our unique biotechnology platform, we have been able to create diverse solutions that are relevant for a wide range of customers in many different markets throughout the world today. That is why our sales remain strong in spite of signs of uncertainty in the global economy and in some of our markets."

In 2013, Novozymes was estimated to have a 48 percent share of the global enzyme market, selling more than 700 products all over the world for applications as diverse as detergents, biofuels, agriculture, food and beverages, biopharmaceuticals, wastewater, textiles and pulp and paper.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email